TrialInternational journal of radiation oncology, biology, physics2022

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.

Jennifer R Bellon et al.PubMed ↗Publisher ↗

No numbers read from the abstract.